BioChromix AB

BioChromix AB is a Swedish in vitro diagnostic company founded in 2004.

In parallel, the Company also develops a unique R&D assay with intended use for target engagement during development of pharmaceuticals for AD that target Amyloid-beta (Aß) and to monitor the effectiveness of ongoing treatment.

BioChromix vision is to translate our development from the laboratories, and on using our unique LCP molecule technology, to develop and deliver new diagnostics and assays for Alzheimer’s disease. BioChromix aim is to be a leading provider of diagnostic methods for AD. The Company’s ambition is also to provide world class R&D assays for soluble Aß aggregates. 

It is BioChromix goal that our products for early stage Alzheimer’s disease diagnostics shall be both user- and patient-friendly. The Company’s methods are based on our novel and patented LCP molecule material.